{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:42:56Z","timestamp":1791934976483,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"vor","delay-in-days":377,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","onlinejacc.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jacc.2016.09.944","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T15:01:28Z","timestamp":1480950088000},"page":"2508-2521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":241,"title":["Causes of Death in Anticoagulated Patients With Atrial Fibrillation"],"prefix":"10.1016","volume":"68","author":[{"given":"Antonio","family":"G\u00f3mez-Outes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Lagunar-Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Isabel","family":"Terleira-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Calvo-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Su\u00e1rez-Gea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Vargas-Castrill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2016.09.944_bib1","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jacc.2010.09.013","volume":"57","author":"Fuster","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.09.944_bib2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.09.944_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.12610","article-title":"Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives","volume":"95","author":"G\u00f3mez-Outes","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jacc.2016.09.944_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.09.944_bib5","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The\u00a0Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2016.09.944_bib6","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2016.09.944_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clin Trials"},{"key":"10.1016\/j.jacc.2016.09.944_bib8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.09.944_bib9","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1161\/CIRCULATIONAHA.112.000491","article-title":"Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study","volume":"128","author":"Marijon","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.09.944_bib10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2016.09.944_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","article-title":"Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial","volume":"125","author":"Hohnloser","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.09.944_bib12","unstructured":"Beasley N, Thompson A. Questions: dabigatran. FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee. September 20, 2010. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM247244.pdf. Accessed May 9, 2016."},{"key":"10.1016\/j.jacc.2016.09.944_bib13","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Pradaxa (dabigatran). Assessment report No.: EMEA\/H\/C\/000829\/X\/13\/G. August 23, 2011. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000829\/WC500110875.pdf. Accessed May 10, 2016."},{"key":"10.1016\/j.jacc.2016.09.944_bib14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.09.944_bib15","doi-asserted-by":"crossref","first-page":"e002197","DOI":"10.1161\/JAHA.115.002197","article-title":"Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF","volume":"4","author":"Pokorney","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2016.09.944_bib16","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2016.09.944_bib17","unstructured":"Beasley N, Dunnmon P, Rose M. Xarelto (rivaroxaban). FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). September 8, 2011. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/ucm270796.pdf. Accessed May 9, 2016."},{"key":"10.1016\/j.jacc.2016.09.944_bib18","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Xarelto (rivaroxaban). Assessment report No.: EMEA\/H\/C\/000944\/II\/0012. September 22, 2011. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000944\/WC500120735.pdf. Accessed May 10, 2016."},{"key":"10.1016\/j.jacc.2016.09.944_bib19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.09.944_bib20","unstructured":"Center for Drug Evaluation and Research. Eliquis (apixaban). Clinical Review Addendum. December 17, 2012. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202155Orig1s000MedR.pdf. Accessed May 9, 2016."},{"key":"10.1016\/j.jacc.2016.09.944_bib21","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Eliquis (apixaban). Assessment report No.: EMEA\/H\/C\/002148\/X\/04\/G. September 20, 2012. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/002148\/WC500136575.pdf. Accessed May 10, 2016."},{"key":"10.1016\/j.jacc.2016.09.944_bib22","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.09.944_bib23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.amjmed.2016.02.028","article-title":"Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 trial","volume":"129","author":"Giugliano","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2016.09.944_bib24","unstructured":"Blank M, McDowell TY, Rose M. Savaysa (edoxaban). FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). October 30, 2014. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM420704.pdf. Accessed May 9, 2016."},{"key":"10.1016\/j.jacc.2016.09.944_bib25","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Lixiana (edoxaban). Assessment report No.: EMEA\/H\/C\/002629\/0000. April 23, 2015. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002629\/WC500189047.pdf. Accessed May 10, 2016."},{"key":"10.1016\/j.jacc.2016.09.944_bib26","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.09.944_bib27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"132","author":"Fox","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.09.944_bib28","doi-asserted-by":"crossref","first-page":"640723","DOI":"10.1155\/2013\/640723","article-title":"Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups","volume":"2013","author":"G\u00f3mez-Outes","year":"2013","journal-title":"Thrombosis"},{"key":"10.1016\/j.jacc.2016.09.944_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13054-016-1265-x","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition","volume":"20","author":"Rossaint","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.jacc.2016.09.944_bib30","first-page":"A11748","article-title":"Edoxaban versus warfarin in patients at increased risk of falling - a subgroup analysis of the ENGAGE AF-TIMI 48 trial","volume":"132 Suppl 3","author":"Steffel","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.09.944_bib31","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/jth.13139","article-title":"Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Chai-Adisaksopha","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2016.09.944_bib32","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.09.944_bib33","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1378\/chest.129.5.1155","article-title":"Effect of study setting on anticoagulation control: a systematic review and metaregression","volume":"129","author":"Van Walraven","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2016.09.944_bib34","doi-asserted-by":"crossref","first-page":"e000067","DOI":"10.1161\/JAHA.112.000067","article-title":"Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial","volume":"2","author":"Singer","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2016.09.944_bib35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.09.944_bib36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bcp.13005","article-title":"Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients","volume":"82","author":"G\u00f3mez-Outes","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2016.09.944_bib37","doi-asserted-by":"crossref","first-page":"i2607","DOI":"10.1136\/bmj.i2607","article-title":"Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study","volume":"353","author":"Wang","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2016.09.944_bib38","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2016.09.944_bib39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00228-016-2078-1","article-title":"Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?","volume":"72","author":"Desmaele","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2016.09.944_bib40","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13104-015-1237-2","article-title":"Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice","volume":"8","author":"Tanislav","year":"2015","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jacc.2016.09.944_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/bcp.12807","article-title":"A\u00a0population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC","volume":"81","author":"Blin","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2016.09.944_bib42","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716364993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716364993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T04:40:57Z","timestamp":1657946457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109716364993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":42,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0735109716364993"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2016.09.944","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727090288.793539279","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.727090288.793529020","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Causes of Death in Anticoagulated Patients With Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2016.09.944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}